133 related articles for article (PubMed ID: 18983038)
1. The use of carbohydrate antigen (CA) 15-3 as a tumor marker in detecting breast cancer.
Agyei Frempong MT; Darko E; Addai BW
Pak J Biol Sci; 2008 Aug; 11(15):1945-8. PubMed ID: 18983038
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
4. Tumor marker CA 15-3 in breast cancer patients.
Fejzić H; Mujagić S; Azabagić S; Burina M
Acta Med Acad; 2015; 44(1):39-46. PubMed ID: 26062696
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study.
Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D
Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994
[TBL] [Abstract][Full Text] [Related]
7. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S
Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053
[TBL] [Abstract][Full Text] [Related]
12. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J
Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132
[TBL] [Abstract][Full Text] [Related]
13. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
15. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels.
Cohen AD; Shoenfeld Y; Gopas J; Cohen Y
Breast Cancer Res Treat; 1994; 30(2):197-200. PubMed ID: 7949217
[TBL] [Abstract][Full Text] [Related]
17. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
18. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
[TBL] [Abstract][Full Text] [Related]
19. Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients.
Laidi F; Bouziane A; Lakhdar A; Khabouze S; Amrani M; Rhrab B; Zaoui F
Asian Pac J Cancer Prev; 2014; 15(11):4659-62. PubMed ID: 24969900
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
